Litcius/Paper detail

Evaluating the Efficacy and Safety of Aflibercept Biosimilar (P041) Compared with Originator Product in Patients with Neovascular Age-Related Macular Degeneration

Reza Karkhaneh, Hooshang Faghihi, Hamid Riazi‐Esfahani, Mojtaba Abrishami, Fatemeh Bazvand, Nazanin Ebrahimiadib, Mohammadkarim Johari, Mohammadreza Akhlaghi, Nasser Shoeibi, M. Hossein Nowroozzadeh, Mohammad‐Reza Ansari‐Astaneh, Hassan Khojasteh, Marjan Imani Fooladi, Alireza Khodabande, Fariba Ghassemi, Elias Khalili Pour, Mohammad Zarei, Ahmad Mirshahi, Farhad Fazel, Hossein Ashraf, Seyedeh Maryam Hosseini, Maryam Dourandeesh, Mostafa Feghhi, Yousef Alizadeh, Hassan Behboudi, Pejvak Azadi, Araz Sabzvari, Hamidreza Kafi, Khalil Ghasemi Falavarjani

2024Ophthalmology Retina19 citationsDOI

Topics & Concepts

AfliberceptMedicineMacular degenerationChoroidal neovascularizationOphthalmologyVisual acuityRandomized controlled trialConfidence intervalClinical trialBevacizumabSurgeryInternal medicineChemotherapyBiosimilars and Bioanalytical MethodsRetinal Diseases and TreatmentsErythropoietin and Anemia Treatment